Co.don

Co.don Current Liabilities

Delisted

The Current Liabilities of Co.don (CNWK.DE) as of Nov 10, 2026 is 2.85 M EUR. In the previous year, Current Liabilities was 3.57 M EUR — a change of -20.08% (lower).

Current Liabilities

2.85 MEUR

YoY

-20.08%

Last updated:

Current Liabilities of Co.don is 2020 2.85 M EUR. Current Liabilities of Co.don was 2019 3.57 M EUR. It decreases by -20.08% lower compared to the previous year.

The Co.don Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2013
610,000.00 EUR
Jan 1, 2014
592,760.00 EUR
Jan 1, 2015
1.09 M EUR
Jan 1, 2016
798,690.00 EUR
Jan 1, 2017
2.99 M EUR
Jan 1, 2018
4.70 M EUR
Jan 1, 2019
3.57 M EUR
Jan 1, 2020
2.85 M EUR
The Co.don Current Liabilities history
YEARCurrent LiabilitiesYoY
2.85 MEUR-20.08%
3.57 MEUR-24.01%
4.70 MEUR+56.91%
2.99 MEUR+274.86%
798,690.00EUR-26.79%
1.09 MEUR+84.06%
592,760.00EUR-2.83%
610,000.00EUR+38.64%
440,000.00EUR+91.30%
230,000.00EUR-17.86%
280,000.00EUR+64.71%
170,000.00EUR-73.85%
650,000.00EUR-18.75%
800,000.00EUR+63.27%
490,000.00EUR-19.67%
610,000.00EUR+22.00%
500,000.00EUR-30.56%
720,000.00EUR+2.86%
700,000.00EUR-59.06%
1.71 MEUR-53.78%
3.70 MEUR+109.04%
1.77 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Co.don Stock analysis

What does Co.don do? Co.don AG is a German company specializing in regenerative medicine. The company was founded in 1993 and is headquartered in Teltow near Berlin. Co.don aims to develop innovative therapies for tissue and joint damage to enable faster recovery for patients. Co.don's business model is based on the concept of tissue engineering. The company produces autologous cell therapies based on a patient's own cells. This means that the patient's own tissue is harvested to cultivate new and healthy cells that can be implanted back into the patient's body. Co.don offers various divisions to best meet the needs of patients. One of the most well-known divisions is cartilage cell therapy, which was developed to provide patients with the opportunity to heal damaged cartilage tissue in a gentle and effective manner. Another area in which the company operates is bone cell therapy. Autologous bone cells are produced to regenerate fractured or diseased bones. The company also has a division for skin-based cell therapy, which aims to heal tissue defects and minimize scarring. Co.don also offers various products tailored to the specific needs of patients. One of the most well-known products is the "Co.don Chondrosphere®" implant, made from autologous cartilage cell tissue. This implant is used to repair cartilage damage in joints and other areas of the body. Another product offered by the company is the "Co.don ViviSpray®" bone substitute material. It is produced by mixing autologous bone cells with a carrier material to promote natural bone formation. In recent years, the company has gained increasing international recognition and is now a well-known player in the field of regenerative medicine. The company has received numerous awards and has conducted several successful clinical trials that demonstrate the effectiveness of Co.don's products. Overall, Co.don AG is a company specializing in the production of autologous cell therapies. The company offers various divisions and manufactures products tailored to the specific needs of patients. With its innovative work, Co.don has contributed to revolutionizing the way tissue and joint damage are treated. Co.don is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co.don stock

Current Liabilities of Co.don is 2.85 M EUR in 2020.

Current Liabilities of Co.don changed from 3.57 M EUR to 2.85 M EUR, representing a -20.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Co.don since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Co.don historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Co.don

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Co.don